Technical Analysis for OVID - Ovid Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical OVID trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| 20 DMA Resistance | Bearish | -0.81% | |
| Bollinger Band Squeeze | Range Contraction | -0.81% | |
| Outside Day | Range Expansion | -0.81% | |
| Bollinger Band Squeeze | Range Contraction | -1.61% | |
| Narrow Range Bar | Range Contraction | -1.61% | |
| NR7 | Range Contraction | -1.61% | |
| Bollinger Band Squeeze | Range Contraction | -1.61% | |
| 200 DMA Resistance | Bearish | -2.39% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 1% | about 14 hours ago |
| 60 Minute Opening Range Breakdown | about 15 hours ago |
| Possible Inside Day | about 16 hours ago |
| 10 DMA Resistance | about 19 hours ago |
| 20 DMA Resistance | about 19 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/09/2021
Ovid Therapeutics Inc. Description
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Disorders Symptoms Neurological Disorders Epilepsy Syndromes Takeda Pharmaceutical Company Urological Disorders Genodermatoses Fragile X Syndrome Sedatives Anticonvulsants Rare Neurological Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.37 |
| 52 Week Low | 2.25 |
| Average Volume | 671,764 |
| 200-Day Moving Average | 3.86 |
| 50-Day Moving Average | 4.06 |
| 20-Day Moving Average | 3.77 |
| 10-Day Moving Average | 3.74 |
| Average True Range | 0.15 |
| ADX | 16.53 |
| +DI | 18.84 |
| -DI | 25.38 |
| Chandelier Exit (Long, 3 ATRs) | 3.65 |
| Chandelier Exit (Short, 3 ATRs) | 4.03 |
| Upper Bollinger Bands | 3.94 |
| Lower Bollinger Band | 3.60 |
| Percent B (%b) | 0.2 |
| BandWidth | 9.11 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.09 |
| MACD Histogram | 0.0033 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.88 | ||||
| Resistance 3 (R3) | 3.89 | 3.84 | 3.85 | ||
| Resistance 2 (R2) | 3.84 | 3.78 | 3.83 | 3.83 | |
| Resistance 1 (R1) | 3.75 | 3.75 | 3.73 | 3.74 | 3.82 |
| Pivot Point | 3.70 | 3.70 | 3.68 | 3.69 | 3.70 |
| Support 1 (S1) | 3.61 | 3.64 | 3.59 | 3.60 | 3.52 |
| Support 2 (S2) | 3.56 | 3.61 | 3.55 | 3.51 | |
| Support 3 (S3) | 3.47 | 3.56 | 3.50 | ||
| Support 4 (S4) | 3.46 |
